- Home
- ALDX vs IVVD Comparison
ALDX vs IVVD Comparison
Compare ALDX & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- IVVD
- Stock Information
- Founded
- ALDX 2004
- IVVD 2020
- Country
- ALDX United States
- IVVD United States
- Employees
- ALDX N/A
- IVVD N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- ALDX Health Care
- IVVD Health Care
- Exchange
- ALDX Nasdaq
- IVVD Nasdaq
- Market Cap
- ALDX 133.7M
- IVVD 123.8M
- IPO Year
- ALDX 2014
- IVVD 2021
- Fundamental
- Price
- ALDX $2.24
- IVVD $0.60
- Analyst Decision
- ALDX Strong Buy
- IVVD Strong Buy
- Analyst Count
- ALDX 2
- IVVD 3
- Target Price
- ALDX $9.50
- IVVD $7.52
- AVG Volume (30 Days)
- ALDX 1.5M
- IVVD 1.9M
- Earning Date
- ALDX 05-20-2025
- IVVD 05-15-2025
- Dividend Yield
- ALDX N/A
- IVVD N/A
- EPS Growth
- ALDX N/A
- IVVD N/A
- EPS
- ALDX N/A
- IVVD N/A
- Revenue
- ALDX N/A
- IVVD $25,384,000.00
- Revenue This Year
- ALDX N/A
- IVVD $606.63
- Revenue Next Year
- ALDX N/A
- IVVD $83.30
- P/E Ratio
- ALDX N/A
- IVVD N/A
- Revenue Growth
- ALDX N/A
- IVVD N/A
- 52 Week Low
- ALDX $1.14
- IVVD $0.36
- 52 Week High
- ALDX $7.20
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- ALDX 36.53
- IVVD 46.86
- Support Level
- ALDX $1.90
- IVVD $0.52
- Resistance Level
- ALDX $2.89
- IVVD $0.80
- Average True Range (ATR)
- ALDX 0.22
- IVVD 0.07
- MACD
- ALDX 0.09
- IVVD 0.01
- Stochastic Oscillator
- ALDX 33.46
- IVVD 32.42
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.